Application of ganoderma lucidum polysaccharide compound in relieving toxicity of cyclophosphamide (CYP)

A technology of Ganoderma lucidum polysaccharide and cyclophosphamide is applied in the application field of Ganoderma lucidum polysaccharide complex in alleviating the toxicity of cyclophosphamide, which can solve the problems of unfavorable polysaccharide, unstable oxidative property, reduced efficacy, etc., and achieves alleviation of oxidative stress and liver damage, improve utilization and biotransformation, overcome the effects of in vivo digestion

Inactive Publication Date: 2020-02-04
TIANJIN UNIV OF SCI & TECH
View PDF0 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The reported molecular weight of Ganoderma lucidum polysaccharides ranges from 2x10^4 to 2x10^6. Large molecular weights are not conducive to polysaccharides crossing multiple cell barriers and entering organisms to exert their activity. Oxidation stability will inevitably lead to loss, which will reduce its efficacy. In order to solve this problem, a method of preparing a compound by combining corn starch and ganoderma polysaccharide

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of ganoderma lucidum polysaccharide compound in relieving toxicity of cyclophosphamide (CYP)
  • Application of ganoderma lucidum polysaccharide compound in relieving toxicity of cyclophosphamide (CYP)
  • Application of ganoderma lucidum polysaccharide compound in relieving toxicity of cyclophosphamide (CYP)

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0015] Example 1: Application of a Ganoderma lucidum polysaccharide compound in alleviating the toxicity of cyclophosphamide; said Ganoderma lucidum polysaccharide compound comprises Ganoderma lucidum polysaccharide and waxy cornstarch; wherein, the mass ratio of Ganoderma lucidum polysaccharide and waxy cornstarch It is 1:4.

[0016] The Ganoderma lucidum polysaccharide complex was prepared in the following manner: Ganoderma lucidum polysaccharide extract and waxy corn starch were added to a planetary ball mill at a mass ratio of 1:4 for grinding at a grinding speed of 700r / min for 6 hours.

[0017] Rat immunosuppression model was established by intraperitoneal injection of cyclophosphamide, and a blank control group (NC), no intervention model group (MC), low dose intervention model group (LPC), high dose intervention model group and high dose control group were established. (HPC), intervention with compound gavage (HP). Determination of oxidative stress and liver injury in...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention belongs to food and particularly relates to application of a ganoderma lucidum polysaccharide compound in relieving toxicity of cyclophosphamide (CYP). The ganoderma lucidum polysaccharide compound comprises ganoderma lucidum polysaccharide and waxy corn starch, wherein the mass ratio of the ganoderma lucidum polysaccharide to the waxy corn starch is 1:4. The prepared ganoderma lucidum polysaccharide and corn starch large-particle compound has functions of effectively relieving oxidation stress and liver injury caused by the CYP. The compound shows a certain anti-digestion characteristic due to physical functions of corn starch and ganoderma lucidum polysaccharide, overcomes defects of in-vivo digestion of ganoderma lucidum polysaccharide, and effectively improves the utilization rate and biotransformation rate of the ganoderma lucidum polysaccharide.

Description

technical field [0001] The invention belongs to food, and in particular relates to the application of a ganoderma lucidum polysaccharide complex in alleviating the toxicity of cyclophosphamide. Background technique [0002] Cyclophosphamide (CYP) is a commonly used anticancer drug in clinical practice, widely used in the treatment of breast cancer, lung cancer, ovarian cancer, cervical cancer, multiple myeloma and other human malignancies. In addition, as a strong immunosuppressant, cyclophosphamide is also commonly used in the treatment of systemic lupus erythematosus, rheumatoid arthritis, polymyositis and other autoimmune diseases. However, while playing a therapeutic role, cyclophosphamide has a variety of toxic and side effects on the body, including bone marrow suppression, liver function damage, cardiotoxicity, hemorrhagic cystitis, etc., which greatly limits its wide application. [0003] Ganoderma lucidum polysaccharide is one of the main active ingredients of Gano...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A23L33/125
CPCA23L33/125
Inventor 周中凯刘雅琪张泊溪
Owner TIANJIN UNIV OF SCI & TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap